22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
21:20 , Apr 28, 2017 |  BioCentury  |  Finance

A different animal?

For the second time, macro factors will make it hard to divine how much impact, if any, a clinical failure at Circassia Pharmaceuticals plc will have on investor sentiment in the U.K. But at least...
07:00 , Jul 21, 2016 |  BC Innovations  |  Strategy

Brexit of brains

Few in the British life sciences sector voiced support for an exit from the EU before last month's referendum, but academics, industry leaders and investors are now weighing up the actual damage as they face...
07:00 , Jun 27, 2016 |  BioCentury  |  Finance

Nine lives?

Whether Circassia Pharmaceuticals plc's implosion will have a lasting effect on the U.K. biotech sector is going to be hard to tease out now that the Brexit has thrown London and the global markets into...
07:00 , May 19, 2016 |  BC Innovations  |  Strategy

Mind the gap

A wave of initiatives and funds in the U.K. over the last two years has been flooding the gap between the country's prolific scientific achievements and its comparatively low rate of commercialization. The hope is...
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Circassia raises expectations

The largest-ever European biotech IPO - by Circassia Pharmaceuticals plc - plus three new filings have buysiders thinking the crack in a European IPO window could be widening. But if Circassia doesn't perform, it could...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Oxford GlycoSciences Ltd. board of directors update

Oxford GlycoSciences Ltd. , Abingdon, U.K.   Business: Drug discovery   Appointed: James Noble, as a non-executive director; formerly finance director, British Biotech plc (BBIOY)  ...
08:00 , Nov 10, 2011 |  BC Innovations  |  Targets & Mechanisms

Countering chemo-induced metastasis

Two independent research teams have elucidated mechanisms by which cisplatin and paclitaxel can promote lung metastases in mice, providing links between the chemotherapies and the known metastatic effects of upregulating VEGF receptor 1 and matrix...
07:00 , Jun 23, 2011 |  BC Innovations  |  Targets & Mechanisms

A bid to revive MMP inhibitors

Matrix metalloproteinases , or MMPs, were once viewed as obvious drug targets-extracellular proteases that are selectively upregulated and play critical functional roles in many diseases. But MMP inhibitors failed in cancer trials a decade ago...
08:00 , Dec 20, 2010 |  BioCentury  |  Strategy

TAP's Big Finish

It has taken nearly three decades, but ImmunoGen Inc. is finally getting some traction with its TAP targeted antibody payload platform. The company has closed out 2010 with a rush of news, and now intends...